Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 17/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4948572 | 0.80 | ELANE (0.44) | KMT2AEP300CREBBP | |
| SCHEMBL17222996 | 0.72 | HCAR2 (0.43) | HCAR2KMT2ATSHR | |
| SCHEMBL5953472 | 0.72 | HCAR2 (0.56) | HCAR2KMT2ATSHREP300CREBBP | |
| SCHEMBL13374012 | 0.70 | CREBBP (0.57) | HCAR2KMT2ATSHREP300CREBBP | |
| SCHEMBL4943590 | 0.66 | AURKA (0.58) | HCAR2KMT2ATSHR | |
| SCHEMBL20818803 | 0.66 | HCAR2 (0.51) | HCAR2KMT2ATSHR | |
| SCHEMBL30128141 | 0.66 | CYP2C19 (0.60) | HCAR2KMT2ATSHR | |
| SCHEMBL4949121 | 0.66 | AURKA (0.62) | HCAR2CREBBP | |
| SCHEMBL14555868 | 0.65 | HCAR2 (1.00) | HCAR2KMT2ATSHRSLC6A4 | |
| SCHEMBL17223055 | 0.64 | ADORA1 (0.49) | HCAR2KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885725-B1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | EP | disclosed |
| EP-1885725-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006108488-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| US-20060235013-A1 | Tricyclic azole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235013-A1 | Tricyclic azole derivatives | CYP3A5, CYP3A43, CYP11B1 | HCAR2 684/4885KMT2A 2810/4885TSHR 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.